Cargando…

Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma

Detalles Bibliográficos
Autores principales:	Liu, Zhi-Peng, Dai, Hai-Su, Su, Xing-Xing, Yang, Yi-Shi, Yin, Xian-Yu, Chen, Zhi-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health, Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431567/ https://www.ncbi.nlm.nih.gov/pubmed/37601477 http://dx.doi.org/10.1097/AS9.0000000000000273

Ejemplares similares

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer
por: CUI, HAI-BIN, et al.
Publicado: (2014)

A commentary on “An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts”
por: Liu, Zhi-Peng, et al.
Publicado: (2023)

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma
por: Kawahara, Kenji, et al.
Publicado: (2022)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma
por: Nakamura, Toru, et al.
Publicado: (2022)

A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma
por: Singhal, Ruchi, et al.
Publicado: (2023)

Ex‐vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy
por: Rossi, Gemma, et al.
Publicado: (2022)

Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
por: Zhang, Yun, et al.
Publicado: (2021)

Meta‐analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma
por: Schorn, S., et al.
Publicado: (2018)

Comment on: Multivariable prediction model for both 90-day mortality and long-term survival for individual patients with perihilar cholangiocarcinoma: does the predicted survival justify the surgical risk?
por: Liu, Zhi-Peng, et al.
Publicado: (2023)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma
por: Paiella, Salvatore, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma
por: Velandia, Carlos, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma
por: Brunner, Robert, et al.
Publicado: (2019)

Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
por: Seo, Dongjin, et al.
Publicado: (2023)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective
por: Kurata, Yoshihiro, et al.
Publicado: (2021)

SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma
por: Fei, Naomi, et al.
Publicado: (2021)

Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report
por: Meyer, Alberto, et al.
Publicado: (2021)

A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)
por: Zheng, Yan, et al.
Publicado: (2021)

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma
por: Jain, Anish J., et al.
Publicado: (2023)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Comment on ‘Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE)’
por: Cao, Meili
Publicado: (2023)

A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020)

Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Xie, Li-Yun, et al.
Publicado: (2022)

The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
por: Su, Yung-Yeh, et al.
Publicado: (2023)

Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)
por: Redegalli, M., et al.
Publicado: (2022)

Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma
por: Amrutkar, Manoj, et al.
Publicado: (2022)

Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma
por: Lan, Xiaoyang, et al.
Publicado: (2023)

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Izadi, Fereshteh, et al.
Publicado: (2021)

A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer
por: Zhou, Haitao, et al.
Publicado: (2016)

Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
por: Liu, Zhi-Peng, et al.
Publicado: (2022)

Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma
por: Petrillo, A., et al.
Publicado: (2022)

Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
por: Yang, Bo, et al.
Publicado: (2022)

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Peng, Pei-Jian, et al.
Publicado: (2015)

Comment On: Liver Transplantation as a New Standard of Care in Patients with Perihilar Cholangiocarcinoma? Results from an International Benchmark Study
por: Wang, Xiang, et al.
Publicado: (2022)

Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study
por: Zhang, Xiu-Ping, et al.
Publicado: (2023)

Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma
por: Limbu, Yugal, et al.
Publicado: (2021)

Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response
por: Xing, Ai-Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8s8ct1drsiojtibbj1gdqkgn22